Our modular system can be adapted to different applications
In Basel, a team of researchers has crossed a quiet but significant threshold in the long human effort to fight disease at its most intimate scale — building tiny machines from biomolecules and nanoparticles that can find cancer cells, deliver a killing blow from within, and then be retrieved, refilled, and sent out again. Led by Cornelia Palivan, the work represents not merely a new medical tool but a new philosophy of design: modular, reusable, and adaptable to problems far beyond the ones it was first built to solve. It is a reminder that the most enduring inventions are not answers to a single question, but frameworks capable of asking many.
- Cancer cells reduced to 16% viability within 72 hours signal that precision, not brute force, may be medicine's most powerful weapon.
- The nanorobots' DNA-based 'molecular velcro' fastening system introduces a programmable flexibility that earlier single-purpose designs could never offer.
- Magnetic propulsion allows researchers to retrieve the robots after deployment — a detail that transforms a disposable tool into a reusable platform.
- The same architecture that hunts HeLa cells in a lab dish could, with a different payload, clean industrial waste or catalyze chemical reactions at the molecular scale.
- Human trials remain years away, held at bay by the vast safety and regulatory terrain that separates a promising laboratory result from a clinical reality.
At the University of Basel, Cornelia Palivan's team has built a nanorobot that operates less like a fixed instrument and more like a reconfigurable toolkit. The machine has two distinct parts: a magnetic propulsion module that drives it through fluid, and a payload capsule that carries therapeutic cargo to a precise destination. The two snap together via complementary DNA strands — molecular velcro that holds the system in a programmable, reversible bond. Swap the contents of the capsule, and the robot's mission changes entirely.
The payload capsule is itself a layered system, housing enzyme-loaded polymer vesicles that can release bioactive compounds selectively — opening only when and where conditions demand. Targeting molecules on the capsule's surface act as a biological key, guiding the nanorobot to dock onto specific cells.
In laboratory tests against HeLa human cancer cells, the results were striking. Fluorescent tracking confirmed the robots found and attached to their targets. When loaded with enzymes programmed to synthesize an anticancer drug directly at the tumor site, cancer cell viability collapsed to 16% within 72 hours — a potency that systemic drug delivery rarely achieves.
Perhaps the most consequential feature is reusability. Because the propulsion module is magnetic, the robots can be recovered after completing their task, disassembled, reloaded, and redeployed. This opens the platform to applications well beyond oncology — industrial catalysis, environmental cleanup, any domain requiring precise molecular-scale work.
Published in Advanced Functional Materials, the research is candid about the distance between lab and clinic. Years of safety testing lie ahead. But what Palivan's team has offered is not a finished answer — it is a flexible architecture, a set of building blocks from which many different futures might be assembled.
In a laboratory at the University of Basel, researchers have built something that sounds borrowed from science fiction but works in the real world: tiny machines made not of circuits and metal, but of biomolecules and nanoparticles, designed to swim through the body and attack cancer cells from the inside.
The team, led by Cornelia Palivan, has engineered what they call a modular nanorobot—a system with two separate, reusable components that snap together on their own. One piece is a magnetic propulsion module that moves the robot through fluid. The other is a payload capsule, a container that carries therapeutic cargo to a specific destination. The two modules connect via a DNA-based fastening system, complementary strands that act like molecular velcro, holding the robot together in a programmable way. What makes this different from earlier nanorobot designs is flexibility. Most existing systems are built for one job only. This one can be reconfigured. Change what goes in the payload capsule, and you change what the robot does.
The payload capsule itself is sophisticated. It contains four enzyme-loaded polymer vesicles—tiny spheres that can process molecules and release products on command. Depending on how they're designed, these vesicles can be opened selectively, releasing bioactive compounds exactly when and where they're needed. The capsule is also equipped with biomolecules that allow the nanorobot to dock onto specific cells or materials, like a key finding its lock.
In the laboratory, the researchers tested their creation against human cancer cells, a line known as HeLa cells. They loaded the nanorobots with fluorescent molecules and watched under a microscope as the machines accumulated on the cell surfaces, proving they could find and attach to their targets. Then came the critical test: they equipped the nanorobots with enzymes that would manufacture an anticancer drug directly at the tumor site. Within 72 hours, the cancer cell viability had dropped to 16 percent. The concentrated local effect of the drug, delivered precisely where it was needed, proved far more potent than systemic delivery would be.
What distinguishes this work is not just the cancer-fighting capability, but the reusability built into the design. Because the propulsion module is magnetic, researchers can retrieve the nanorobots after they complete their task, separate the two modules, refill the payload capsules with new cargo, and reassemble them. This opens possibilities far beyond medicine. In industrial catalysis, in environmental remediation, in any domain where you need tiny machines to do work at the molecular scale, the same basic platform could be adapted simply by changing what the payload capsule carries.
Palivan and her team published their findings in Advanced Functional Materials. They acknowledge that using these nanorobots in human patients remains a distant goal, requiring years of additional research and safety testing. But the modular architecture they've created suggests a path forward—a flexible platform that could be customized for countless applications, each one built from the same fundamental building blocks. The nanorobot, in other words, is not a finished product but a toolkit.
Notable Quotes
Previous nanorobots are often designed for a specific task only. Our modular system can be adapted to different applications.— Cornelia Palivan, University of Basel
The drug can have a concentrated local effect if we use our nanorobot to specifically target it to the cancer cells.— Voichita Mihali, lead author of the study
The Hearth Conversation Another angle on the story
Why does it matter that these modules are reusable? Couldn't you just make new ones each time?
Cost and waste. If you're running experiments or treating many patients, making fresh nanorobots every time becomes expensive and generates molecular-scale garbage. Being able to refill and reuse the same propulsion module means you're thinking about this as infrastructure, not disposable tools.
The DNA velcro—is that the breakthrough, or is it the cancer-killing part?
Neither alone. The DNA fastening is elegant because it's programmable—you can design which modules snap together and in what order. But what makes the whole system work is that you can swap payloads. The cancer test was proof of concept. The real innovation is the flexibility.
Sixteen percent viability in 72 hours sounds impressive. How does that compare to current cancer treatments?
In a petri dish, it's a strong result. But this is HeLa cells in controlled conditions. Getting the same effect in a living body, navigating through tissue, avoiding the immune system, reaching tumors that are buried deep—that's years of work away. The lab result shows the principle works. The hard part is making it work in humans.
You mentioned these are made of biomolecules, not electronics. Does that mean the body can break them down?
That's actually an advantage they're counting on. Biomolecules are biodegradable. You don't want permanent machines floating around your bloodstream. The challenge is making them durable enough to reach their target and do their job, but not so stable that they persist after they're done.
What stops someone from using this for something harmful?
That's a real question, but it's not unique to nanorobotics. Any powerful tool can be misused. The researchers are publishing their work openly because that's how science works. The hope is that the benefits—targeted drug delivery, environmental cleanup, industrial precision—outweigh the risks, and that oversight keeps pace with the capability.